Assertio reports first quarter 2023 financial results, raises full year 2023 outlook

Net product sales increase 18% year-over -year raises full year outlook to net product sales of $157 to $167 million, adjusted ebitda $90 to $98 million to acquire spectrum pharmaceuticals in all stock and cvr transaction, expected to be significantly accretive to adjusted eps and operating cash flow in 2024 lake forest, ill., may 09, 2023 (globe newswire) -- assertio holdings, inc. (“assertio” or the “company”) (nasdaq: asrt), a specialty pharmaceutical company offering differentiated products to patients, today reported financial results for the first quarter ended march 31, 2023.
ASRT Ratings Summary
ASRT Quant Ranking